[Federal Register Volume 64, Number 46 (Wednesday, March 10, 1999)] [Notices] [Page 11923] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 99-5914] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, Phase I Clinical Studies/Phase II Clinical Trials of New Chemopreventive Agents. Date: March 30, 1999. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: Executive Plaza North, Conference Room F, 6130 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Gerald G. Lovinger, Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard/EPN--Room 630D, Rockville, MD 20892-7405, 301/496-7987. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398; Cancer Research Manpower, 93.399, Cancer Control, National Institutes of Health, HHS) Dated: March 3, 1999. LaVerne Y. Stringfield, Committee Management Officer, NIH. [FR Doc. 99-5914 Filed 3-9-99; 8:45 am] BILLING CODE 4140-01-M